Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ali McBride

Showing results (11-20 of 145) with videos related to

Pageof 15
Sort By:
Journal of Medical Economics|December 6, 2021
Economic evaluation of polatuzumab-bendamustine-rituximab <i>vs.</i> tafasitamab-lenalidomide in transplant-ineligible R/R DLBCLMatthias Calamia, Ali McBride, Ivo Abraham
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|October 16, 2019
Pharmacist perspectives and considerations for implementation of therapeutic oncology biosimilars in practiceSandra Cuellar, Ali McBride, Patrick Medina
Journal of the National Comprehensive Cancer Network : JNCCN|November 2, 2016
Arguing (About) the Value of Cancer CareIvo Abraham, Ali McBride, Karen MacDonald
Oncology (Williston Park, N.Y.)|November 29, 2013
Oral oncolytics: Part 2--legislation targeting cost & access, and other initiatives to reduce costsRobert Mancini, Ali McBride, Mary Kruczynski
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|October 16, 2019
Treatment with pembrolizumab after hypersensitivity reaction to nivolumab in a patient with hepatocellular carcinomaBriana Choi, Ali McBride, Aaron J Scott
Future Oncology (London, England)|August 12, 2021
Conversion to biosimilar pegfilgrastim-cbqv enables budget-neutral access to FOLFIRINOX treatment for metastatic pancreatic cancerKaren MacDonald, Neda Alrawashdh, Ali McBride, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|February 20, 2015
Carfilzomib: a second-generation proteasome inhibitor for the treatment of multiple myelomaAli McBride, Jeff O Klaus, Keith Stockerl-Goldstein
Journal of Medical Economics|October 7, 2020
Cost-efficiency and expanded access of prophylaxis for chemotherapy-induced (febrile) neutropenia: economic simulation analysis for the US of conversion from reference pegfilgrastim to biosimilar pegfilgrastim-cbqvKaren MacDonald, Ali McBride, Neda Alrawashdh, et al.
Future Oncology (London, England)|November 8, 2021
Expanded access to anticancer treatments from conversion to biosimilar pegfilgrastim-cbqv in US breast cancer patientsAli McBride, Neda Alrawashdh, Karen MacDonald, et al.
Journal of the Advanced Practitioner in Oncology|June 27, 2022
Evaluation of Emergency Department Visits by Oncology Patients: A Running Comparison to Admissions and ED Visits Under the CMS OP-35 RulingNada Alsuhebany, Jamie Brown, Jacquelyne Echave, et al.
Pageof 15

Showing results (11-20 of 145) with videos related to

Sort By:
Pageof 15
Journal of Medical Economics|December 6, 2021
Economic evaluation of polatuzumab-bendamustine-rituximab <i>vs.</i> tafasitamab-lenalidomide in transplant-ineligible R/R DLBCLMatthias Calamia, Ali McBride, Ivo Abraham
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|October 16, 2019
Pharmacist perspectives and considerations for implementation of therapeutic oncology biosimilars in practiceSandra Cuellar, Ali McBride, Patrick Medina
Journal of the National Comprehensive Cancer Network : JNCCN|November 2, 2016
Arguing (About) the Value of Cancer CareIvo Abraham, Ali McBride, Karen MacDonald
Oncology (Williston Park, N.Y.)|November 29, 2013
Oral oncolytics: Part 2--legislation targeting cost & access, and other initiatives to reduce costsRobert Mancini, Ali McBride, Mary Kruczynski
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|October 16, 2019
Treatment with pembrolizumab after hypersensitivity reaction to nivolumab in a patient with hepatocellular carcinomaBriana Choi, Ali McBride, Aaron J Scott
Future Oncology (London, England)|August 12, 2021
Conversion to biosimilar pegfilgrastim-cbqv enables budget-neutral access to FOLFIRINOX treatment for metastatic pancreatic cancerKaren MacDonald, Neda Alrawashdh, Ali McBride, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|February 20, 2015
Carfilzomib: a second-generation proteasome inhibitor for the treatment of multiple myelomaAli McBride, Jeff O Klaus, Keith Stockerl-Goldstein
Journal of Medical Economics|October 7, 2020
Cost-efficiency and expanded access of prophylaxis for chemotherapy-induced (febrile) neutropenia: economic simulation analysis for the US of conversion from reference pegfilgrastim to biosimilar pegfilgrastim-cbqvKaren MacDonald, Ali McBride, Neda Alrawashdh, et al.
Future Oncology (London, England)|November 8, 2021
Expanded access to anticancer treatments from conversion to biosimilar pegfilgrastim-cbqv in US breast cancer patientsAli McBride, Neda Alrawashdh, Karen MacDonald, et al.
Journal of the Advanced Practitioner in Oncology|June 27, 2022
Evaluation of Emergency Department Visits by Oncology Patients: A Running Comparison to Admissions and ED Visits Under the CMS OP-35 RulingNada Alsuhebany, Jamie Brown, Jacquelyne Echave, et al.
Pageof 15